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Abstract
Mass production was part of the industrial revolution in 1870 and, with it, a 
huge step change in manufacturing processes. Its impact was ground breaking and 
became even more remarkable with automation in a business production environ-
ment. The chemical industry is one of the manufacturing sectors that has benefited 
from the technology of mass production achieved through automating the business 
process. In this era of industry 4.0 and with the associated advanced technologies 
of smart manufacturing, cloud computing, cyber physical systems and internet of 
things, mass production has been revolutionised but still faced issues such as quality 
control of the production process which was affected by supply chain management, 
customised production of commodity and specialty chemicals and huge demand 
from other chemical industry manufacturers. This chapter has reviewed the evolu-
tion of mass production during traditional manufacturing to the present day and 
carried out a risk assessment to quality of production in a mass production environ-
ment with a view to recommending adequate quality control of the production 
process. The chapter also included a case study for mass production of a phar-
maceutical drug—Amoxicillin which was partly batch produced into dry powder 
and then mass produced using tableting and encapsulating machine, highlighting 
sources of contamination and inconsistency in tablet weight if adequate control 
measures were not put in place.
Keywords: mass production, quality control, chemical industry, risk assessment, 
manufacturing, tableting/encapsulating
1. Introduction
Manufacturing is essential to a nation’s economic well-being and quality of life for 
citizens because it creates wealth which is distributed through high-value jobs. Since 
its birth two centuries ago, the manufacturing industry has evolved through several 
paradigms [1]. The first paradigm was craft production which created the product 
requested by the customer at a relatively high cost. The reason is that there were no 
manufacturing systems associated with this paradigm. Also, craft production was 
confined to localised geographical regions and such production process was not scal-
able or interchangeable. Subsequently, the moving assembly lines then enabled the 
development of mass production which provided low-cost products through large 
scale manufacturing. However such production was limited in variety, as evidenced 
by the famous statement about colour that he wanted so long as it was black.
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Mass production evolved as a method of producing goods in large quantities 
at a low cost per unit. It was kicked off with a moving assembly line at Highland 
Park near Detroit, Michigan named after Henry Ford. Mass production was fully 
established and massively utilised at the end of the World War II when demand for 
consumer products became very high [1]. This technology was sought after because 
of the concepts of parts interchangeability, moving assembly lines and scientific 
management which are key enablers for mass production. While mass production 
created tremendous wealth for the U.S. and many individuals, it also had several 
weaknesses. Although massively revolutionised, it still faced issues such as qual-
ity control of the production process attributed to supply chain management, 
customised production of commodity speciality chemicals and huge demand from 
other chemical industry manufacturers. This book chapter therefore will review the 
evolution of mass production during traditional manufacturing to the present day 
and then carry out a risk assessment of quality of production in a typical chemical 
industry mass production environment with a view to managing and recommend-
ing adequate quality control of the mass production process.
In the late 1980s, global competition and consumer demand for high product 
variety led to the development of mass customisation. This was achieved by 
manufacturers designing the basic product architecture and possible options while 
customers selected the assembly combination of their choice. Product family plan-
ning then enabled manufacturers to share certain common components for a range 
of family of products.
Figure 1 shows how mass production with a key objective of economy of scale 
can be differentiated from mass customisation involving mass production of 
specific products for a large variety of customers while exploiting the economy of 
scope. Another option is personalisation which designs/produces products which 
are personalised for individuals thereby achieving a high level of value differentia-
tion for specific users.
Figure 2 shows that the goal of mass production is scale while for mass customi-
sation it is both scale and scope of production. For personalised production the 
goal is scale, scope and value derived. Overall, the desired product characteristics 
is quality and cost during mass production, quality, cost and variety for mass 
customisation and quality, cost, variety and efficacy for personalised production. 
It is therefore assumed that during mass production the customer buys the product 
while during mass customisation the customer chooses what they wish to buy. A 
request for personalised production requires the customer to design, choose and 
then buy the product.
During mass production, mass customisation and personalised production the 
emphasis and key objective is to produce very large quantities of the product within 
Figure 1. 
Goals of the manufacturing paradigms [1].
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a limited time scale to satisfy customer demand. Monitoring manufacturing quality 
therefore could prove difficult considering that satisfactory product quality can 
only be achieved by rapid screening of materials at the input stage, transformation 
process stage within the manufacturing hub and finally at the output stage before 
shipment to the customer. The aim of this chapter therefore, is to review a typical 
mass production process, understand current practice to guaranteeing quality 
assurance during mass production and finally propose how this can be implemented 
in the chemical industry. It will also develop risk assessment that could guide 
process quality monitoring during mass production.
2. Background and literature review
There are four industrial revolutions so far [2] including first industrial revolu-
tion associated with discovery of water and steam power engine in 1784, the second 
industrial revolution in 1870 which involved mass production using electrical energy, 
the third industrial revolution in 1970 which introduced the use of information 
technology systems for automation and the fourth industrial revolution describ-
ing the present day which embraces Internet of Things (IOT) and cyber physical 
systems (CPS). The industrial revolutions which commenced over three centuries 
ago therefore have evolved and formed the backbone of manufacturing with 
each revolution providing a boost to productivity in the sector. Since the second 
industrial revolution mass production has sustained high volume production to 
satisfy global demand and needs. The manufacture of cars, guns and fast food are 
examples of mass production. It is the machine tool industry that gave rise to the 
idea of mass production because it motivated innovators in Britain and the United 
States to commence production of interchangeable parts.
Henry Ford was known to have invented an improved version of the assembly 
line for mass production when he mass produced the Curved Dash Oldsmobile. 
Ransom Eli Olds in 1901 in the USA. On this occasion he was said to have conceived 
the basic concept of the assembly line out of which 425 Curved Dash Oldsmobiles 
Figure 2. 
Differences between mass production, mass customization and personalised [1].
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were manufactured. This significant development led the automotive manufactur-
ing market over a period of 3 years from 1901 to 1904 [2]. It was also noteworthy 
that Henry Ford improved his design and installed the first conveyor belt assembly 
line around 1913 which reduced the building time of the Model T version to just 
93 minutes. During that period, Ford became the world’s-largest car manufacturer, 
having produced more than 15 million Model Ts by 1927 using the enhanced assem-
bly line concept.
Other sectors have benefitted immensely from mass production such as the fast 
food and electronics industries to name a few. In the food industry, for instance, 
beverages, canned and bottled soft and alcoholic drinks and dried food packs are 
mass produced daily to satisfy huge global demand.
The advantages of mass production are [2]:
a. It is usually ‘automated’ to the highest extent possible.
b. Labour costs are reduced substantially.
c. It engenders a faster rate of production.
d. Although capital and energy investment are increased total expenditure per 
unit of product is decreased.
e. Rate of production is enhanced.
The disadvantages of mass production are:
a. Mass production infrastructure is very expensive to set up.
b. The workers are not highly motivated, since their work is very repetitive.
c. Manufacturing system is not very flexible, and production line is difficult to 
adapt.
d. If one part of the line breaks, the whole production process will halt until it is 
repaired.
2.1 Quality management during mass production
During mass production, mass customisation and personalised production the 
emphasis and key objective is to produce very large quantities of the product within 
a limited time scale to satisfy demand. Monitoring the entire manufacturing process 
in terms of quality therefore could prove difficult considering that satisfactory 
manufacturing quality can only be achieved by rapid screening of materials at the 
input stage, transformation process stage within the manufacturing hub and finally 
at the output stage before shipment to the customer.
Recalls from mass production such as for cars, processed food and aircrafts 
have frequently been reported, even for the case where the rate of defects is only 
of the order of ppm or less. Even if the defect rate is of the order of ppm or less, 
most of the remaining safe products would also need to be recalled and may be 
destroyed or replaced by new ones. Such recalls are always cost intensive. During 
mass production it is very difficult using conventional quality control methods 
to find defects of the order of ppm or less at the stage of design and production. 
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Murakami [3] researched on a solution that could obviate the recall problem of 
the order of ppm during mass production. His new quality control method detects 
defects of the order of ppm or less for mass production products. This was based 
on the statistics of extremes successfully applied to the fatigue strength evaluation 
of defective materials. He confirmed that the same method could be applied, not 
only to mass production, but also for large machine components produced in large 
numbers.
Figure 3 shows hypothetical model of an input, manufacturing transformation 
and output for a production process. Input to the process could be in form of raw 
materials, catalysts and information; the transformation process involves a transi-
tion stage where the input materials are combining under the relevant conditions, 
such as temperature, pressure, etc. to produce the target output. The model shows 
that for each of the three stages there would need to be control in place to achieve 
the target/desired quality. In a mass production/continuous processing environment 
it may not be feasible to evaluate every single item going through the process and 
also at the output. Rather, acceptance sampling is used for quality assurance.
Siddiqui et al. [4] have reviewed the applications of analytical techniques 
including acceptance sampling in pharmaceutical analysis of drugs. They confirmed 
that pharmaceuticals may develop impurities at various stages of their develop-
ment, transportation and storage, Consequently they need to be characterised and 
components quantified.
Table 1 shows common analytical techniques for quality control during mass 
production of chemicals. During chemical manufacture process analytical tech-
niques are used to measure bulk materials, intermediates, impurities and degrada-
tion products. The aim is to characterise the quality of materials by setting limits of 
their active ingredient content [4].
The common analytical methods presented in Table 1 include titrimetry, 
chromatography, spectroscopy, electrophoresis, electrochemical methods and 
electrophoresis.
Acceptance sampling as a statistical method is also used to inspect bulk 
materials and mass-produced products to determine if they meet the required 
specifications. Acceptance sampling plan guarantees that the average quality level 
or percent defectives actually produced for consumers will not exceed a specified 
limit. It is therefore an effective way to ensure the high quality of mass-produced 
products and is usually conducted on the basis of a reference standard, or system 
of inspection rules [4].
Figure 3. 
Model for quality control during mass production.
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Quality analysis by acceptance sampling is measured by the following  
variables [5]:
a. Acceptable quality level (AQL): this is the desired quality level at which the 
probability of acceptance is high. It is described as the maximum proportion of 
defectives which the consumer finds acceptable. it is therefore the maximum 
percent defectives that can be considered satisfactory during sampling.
b. Lot tolerance percent defective (LTPD) or reject able quality level (RQL): this 
is the quality level at which the probability of acceptance is low and below this 
level the batch is rejected. This could be described as the dividing line between 
good and bad lots. Lots at this quality level however, are considered to be poor 
and are classed as average outgoing quality (A.O.Q )
Advantages of acceptance sampling:
i. It is applicable to industries where there is mass production which follows a 
set production procedure.
ii. The method is economical and easy to understand.
iii. Products that are delicate to handling during inspection can be inspected by 
sampling.
iv. Acceptance sampling enhances scheduling and delivery times.
Limitations of acceptance sampling:
i. Sampling does not guarantee 100% batch quality and there is risk of sub-
standard output.
Process analytical technique (PAT) Variants of the technique
(1) Chromatography a. High performance thin layer chromatography
b. Thin layer chromatography
c. High performance liquid chromatography
d. Gas chromatography
(2) Spectroscopy a. Nuclear magnetic resonance spectroscopy
b. Infra-red spectroscopy













Common analytical techniques used for quality control during batch and mass production.
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ii. Success of the system is dependent on, sampling randomness, quality char-
acteristics to be tested, batch size and criteria of acceptance of lot.
• Producer’s and consumer’s risk: the acceptance or rejection of the whole batch 
of products in acceptance sampling depends upon the results of the sample 
inspected. There is always a chance that a sample may not be true representa-
tive of the batches or lots from which it is drawn. Consequently, there are two 
types of risk;
• Producer risk (α): probability of a batch being good overall or even better 
than acceptable quality level (AQL) but due to bad sampling it is rejected. So 
this probability of rejection of a good lot which otherwise would have been 
accepted is known as producer’s risk (α).
• Consumer risk (β): probability of a bad batch or substandard quality being 
accepted however produces a good sample and consequently accepted. So this 
probability of a defective lot being accepted which otherwise would have been 
rejected is known as consumer risk (β).
Guoa et al. [6] designed a quality control mechanism by scoring the quality 
of input, the transformation process and the output score. In their study they 
developed a six component process analysis turtle diagram quality scoring 
system. The assessment system is based on input material resources, the process 
support, quality control standard, quality manufacturing control method and 
the output, forming a quality control mechanism analysis model presented as a 
radar map.
Figure 4 adapted from [6] shows the radar model for quality control mechanism 
during manufacture. It shows the six variables that would need to be monitored 
during a production process as input, output, quality monitoring, quality control 
standards, process support and physical resources. It also shows the levels of expec-
tation for the variables measured quantitatively.
Switching from batch to continuous pharmaceutical mass production offers 
several advantages, such as increased productivity, steady product quality and 
decreased costs. Kirchengast et al. [7] presented a control strategy for direct 
compaction on a continuous tablet production line consisting of two feeders, one 
blender and a tablet press (TP). They also applied a data-driven, linear model-
ling approach to develop a Smith predictor for active pharmaceutical ingredient 
concentration control and a model predictive controller responsible for the TP 
hopper level. In case of severe concentration variations the system could discard 
 out-of-specification material before it entered the TP. The authors tested effective-
ness of the control concept in a simulation as well as by implementing it on a real 
pilot plant.
Mass manufacture of micro products in the present day is quite challenging 
since tools, materials and technologies have to be scaled down from the macro to 
the micro domain. This is mainly because downscaling of the basic classical process 
would lead to unexpected process behaviour which poses new challenges for in-
process quality inspection desiring a reliable quality control. To implement this in 
a mass production environment therefore, new strategies to plan the process while 
focussing on the logistics of the quality parameters would become essential. Weimer 
[8] introduced a closed-loop quality control strategy for bulk production in micro 
cold forming. A discrete event simulation model incorporating characteristics of 
optical quality inspection and general process parameters allows the quantification 
of the system’s performance.
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2.1.1 Quality control strategies for mass production
A three-level quality control strategy for a continuous manufacturing pro-
cess was proposed to maintain the quality of the product in response to potential 
variations or disturbance in the process, equipment conditions, incoming raw 
materials, or environmental factors over time Yu et al. [9]. A Level-3 quality 
control strategy imposes strict constraints on attributes and parameters that 
could affect product quality while also relying on rigorous end-product testing 
that should guarantee final product quality. Tight quality control of this nature 
is also used in a batch manufacturing environment and quality by testing (QbT) 
situation. This is managed by tracking a manufacturing operation to ensure 
that relevant parameters are maintained within the desired constraint. It is also 
necessary at the early stage of drug development to have a clear understand-
ing of how raw material and process variability could affect product quality to 
fully appreciate the level of quality control. There is a perceived view that this 
approach is not feasible to be effectively implemented in continuous manufac-
turing processes.
The US Food and Drug Administration (FDA) recognised that increased testing 
does not necessarily improve product quality and thus quality must be built into the 
product [10], following the QbD concept. Consequently, pharmaceutical quality by 
Figure 4. 
Model for quality control mechanism.
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design (QbD) has now evolved guided by standardised documents associated with 
Pharmaceutical Development, Quality Risk Management, Pharmaceutical Quality 
System and Development and Manufacture of Drug Substances [10].
Quality by design (QBD) finally matured and evolved into quality by control 
(QbC) which describes the design and operation of a robust manufacturing system. 
This is normally achieved by an integrated and comprehensive process control 
underpinned by automation principles and also based on a clear understanding of 
the process. Overall therefore, Quality by Control enables a continuous monitoring 
and control of process operations and systematic release of the correct specification 
of manufactured products in real time.
Figure 5 shows a plot of drug quality in development stages vs. Product and 
Process knowledge. It demonstrates the evolutionary process of batch manufactur-
ing through to continuous manufacturing and then smart manufacturing and the 
corresponding quality assurance checks in place. As drug quality development 
progresses from the batch to continuous and then smart manufacturing, quality 
assurance changes from quality by testing to quality by design and then consolidat-
ing to quality by control based on standards and requirements.
2.1.2 Quality control during bulk pharmaceutical production
In continuous chemical production lines, materials are transformed into final 
products and by-products and sometimes the activities take place in different 
departments. Overall, the quality of the final products is dependent on the quality 
of the input materials, the state of the relevant manufacturing equipment and the 
performance of the operators. However, out of control situations along produc-
tion lines would normally lead to loss in operation time, material and financial 
resources. Sahebjamnia et al. [11] proposed a Fuzzy Q-learning Multi-Agent Quality 
Control System (FQL-MAQCS) to control a continuous chemical production line. 
The system manages unforeseen circumstances during production through a multi-
agent based system. It consists of quality control executor, process data analyst, 
central decision-maker, departmental decision-maker and knowledge/rule manager 
agents. The system is also self-learning, updated periodically and information 
gathered could be stored in a knowledge base. FQL-MAQCS has been tested in a 
real case study situation and the results demonstrate the usefulness, robustness and 
capability of the developed quality control system.
Figure 5. 
The systematic progression in quality assurance via QbT, QbD and QbC [10].
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Pharmaceutical production is now progressing more into mass personalization, 
down to lot size N = 1. Each product is not only produced as part of a batch during 
mass production but it is also designed uniquely for the benefit of a specific patient. 
Based on demand certain drugs are custom designed and manufactured for large 
hospital or community pharmacies. An ongoing trend is an increased usage of 
contract manufacturing/filling by most pharmaceutical companies. Highly flexible 
aseptic production and filling lines have now become trendy until recently was not 
feasible through filling line concepts available in the present day but only through 
highly flexible automated systems driven by robotics [12]. The popular technology 
of individualised/customised mass production of cars in terms of colour, engine 
specification and performance, wheels, lighting and extras is still remote in cur-
rent pharmaceutical production technologies. If successfully implemented, this 
would be a revolution in pharmaceutical manufacturing and also for the Food and 
Drug Administration (FDA). Bhaskar [13] designed an advanced model predictive 
control (MPC) architecture integrated with a novel real-time tablet weight mea-
surement method aimed to develop and implement continuous direct compacting 
tablet manufacturing pilot-plant which has the potential to control tablet weight 
and tablet breaking force simultaneously by systematically decoupling and cascad-
ing the control loops. The predictive control algorithm (PCA) was superior to the 
proportional, integral and derivative (PID) controller and consequently could be 
utilised for a wide range of applications to improve the quality of pharmaceutical 
products during continuous manufacturing. The MPC enabled control of the main 
compression force and pre compression force using main compression height and 
fill depth respectively as the actuators. The researchers claimed that developing 
this technology made it possible to measure tablet weight and other variables that 
enhanced manufacturability of pharmaceutical tablets.
Lakerveld et al. [14] in a separate study designed a plant-wide control structure 
for a continuous pharmaceutical pilot plant used to classify control objectives. By 
means of simulation software they demonstrated that for selected parameters the 
critical quality attributes (CQAs) of the final product can be kept close to specifica-
tion in the presence of significant and persistent disturbances. This shows flexibility 
to control CQAs independently of each other.
Mesbah et al. [15] developed a control strategy based on a non-linear moment 
model whose optimal operation was based on manipulation of heat input to a 
crystallizer such that a maximal allowable crystal growth rate was maintained dur-
ing a production process. The feedback structure of the control framework enabled 
the optimizer to reject process uncertainties and accurately account for plant-model 
mismatch while fulfilling product quality requirements.
Advanced feedback control concepts which are capable of improving perfor-
mance of batch processes, as well as enable technologies from batch to continu-
ous manufacturing were developed by Nagy et al. [16]. These were used in the 
improvement of pharmaceutical particulates, especially in the application to 
continuous drug substance/product manufacturing. Mathematical modelling of 
the optimal design, start-up and control of anti-fouling and continuous crystal-
lisation processes to achieve and maintain the desired controlled stage of operation 
was demonstrated. Su et al. [17] demonstrated the use of a rotary tablet press, 
integrated into a pilot scale continuous direct compaction process. The outcome was 
that active process control which was based on product and process knowledge and 
advanced model-based techniques, data reconciliation, model predictive control 
and risk analysis, appeared to be indispensable when implementing a comprehen-
sive Quality by Control. It also appeared to guarantee robustness and production 
efficiency. Recently, Singh [18] developed an automated version of the continuous 
pharmaceutical manufacturing pilot plant. The feeder, comill, blender and tablet 
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press unit operations of the pilot plant were integrated with a centralised control 
platform enabling the whole plant to be operated automatically. Data generated 
from all the unit operations were capable of being collected and stored systemati-
cally in a data base.
2.1.2.1 Contamination quality control during manufacturing
Contamination quality control is a huge challenge during manufacturing 
especially for products with ultra-low tolerance for impurities and contaminants. 
For instance during the manufacture of premium chemicals, highly sterile pharma-
ceuticals and hygienic products and other products with high purity requirements 
and specifications, it is essential to provide an environment that will obviate any 
form of contamination. A common source of contamination is from manufactur-
ing machines and equipment that can conceal microscopic particles and microbes. 
Decontamination can be achieved through effective cleaning and disinfecting 
manufacturing equipment at regular intervals and ensuring that all surfaces exposed 
to raw materials and products can be reached by the cleaning and disinfection pro-
cesses. Hydrogen peroxide is widely recommended for the cleaning and fumigation 
process and therefore all machine housing and operating components and interfaces 
need to be robustly designed to minimise any form of contamination from these. 
Manufacturing equipment therefore should be designed to be resistant to chemicals, 
display low adsorption affinity for hydrogen peroxide during fumigation and also its 
rapid desorption during aeration in order to speed up the production process [12].
Kraemer et al. [19] researched on clean ability test of a robot contamination with 
a water-based fluorescing test contamination. The researchers mixed riboflavin in 
ultra-pure water which was then allowed to dry onto the manufacturing surfaces. 
On inspection under UV light before ultra and after manual wipe cleaning with a 
pre wetted polyester knitting cleanroom wipe using ultrapure water, they observed 
areas that were difficult to clean because of the use of the fluorescing pigment 
riboflavin. This included depressions, indentations and edges.
3.  Case study: process flow diagram for the manufacturing process 
of amoxicillin
Amoxicillin oral suspension is an antibiotic which most commonly utilised for 
first line treatment of middle ear infections and for pneumonia, skin infections and 
strep throat as well. Active compound used in its formulation has chemical formula 
C16H19N3O5S with molar mass of 365.4. It is also called phenoxymethyl penicillin. 
Figure 6 shows a variety of Amoxicillin capsules and tablets while Figure 7 shows the 
structural formula of Amoxicillin.  Figure 8 is GSK Manufacturing Plant at Irvine.
Figure 9 shows the process flow diagram for manufacture of Amoxicillin [20]. 
The process starts from stage A involving the reaction of the relevant raw materi-
als [6-aminopenicillanic acid (6 APA), water and hydroxy phenyl glycine methyl 
ester (HPGME) and phenyl glycine acylase (PGA)] necessary for manufacture and 
finishes at stage O which is the drying process. Quality control of the manufactur-
ing process takes place at every stage to ensure that the finished product in a dried 
form has the target consistency of 100% amoxicillin with minimum impurity. Most 
of the unit operations up till this stage are mainly batch manufacturing processes. 
The dried amoxicillin powder would need to be quality tested by acceptance 
sampling using relevant analytical techniques to establish conversion consistency 





Structural formula of amoxicillin (6-aminopenicillanic acid).
Figure 8. 
GSK manufacturing Plant at Irvine (GSK Website).
3.1 Quality control of the tableting/encapsulating process
The dried amoxicillin produced according to Figure 9 will now be mass pro-
duced into tablets and capsules using automated tableting (Figure 10). Tablets are 
normally manufactured by direct compression or by granulation depending on 
material properties and the relevant requirements for formulation. During tablet 
manufacture the powder is fed to the machine and blended before tableting unit 
Figure 6. 
Amoxicillin capsules and tablets.
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operations kick off. The mass production process would also need to be monitored 
for consistency by strict quality control procedures.
The tablet press is a multi-stage process split up into stations with each sta-
tion going through the routine of die filling, metering, pre-compression, main-
compression, tablet ejection and take-off from lower punch, as shown in Figure 10. 
After the blend is fed into the die, the metering stage is adjusted to achieve the 
dosing position, i.e. the volume of powder inside the die. The powder is then locked 
between upper and lower punches during pre-compression and main-compression 
until the tablet ejection and take-off stages are reached. The pre-compression stage 
serves to remove air trapped in the die and to rearrange the particle packing, while 
the main compression stage compacts and transforms the powder bed into a tablet. 
The tablet weight can be controlled by changing the dosing position subject to 
variations in powder bulk density, and in filling time due to changes in turret speed, 
or in filling efficacy due to changes in powder flow properties. The in-die tablet 
thickness is determined by the punch displacement which is manually set before 
the tableting operation for the tablet press used in this study. Hence, the maximum 
Figure 9. 
Process flow diagram for the manufacture of amoxicillin [20].
Figure 10. 
Tablet weight measurement real-time monitoring and control [17].
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main-compression force depends on the amount of powder in the die or, equiva-
lently, on the tablet weight.
3.2  Risk assessment of quality assurance and control during mass production 
of chemicals
Table 2 shows potential risk variables associated with quality control during 
mass production. It ranges from issues associated with acceptance sampling of 
materials and products at the input/output stage to contamination from tableting 
machines, impure product and variation in tablet weight.
Tian et al. [21] carried out quality risk assessment and mitigation of pharma-
ceutical continuous manufacturing of a case study using flowsheet modelling 
approach (an engineering approach that can provide a framework to understand 
the impact of process dynamics on drug quality and associated risks during 
production, thereby facilitating the development of robust continuous pro-
cesses) and identified a potential area for model improvement. Using sensitivity 
analyses they identified the significance of process parameters and material 
attributes on the dynamic responses and quality attributes of the tablet. They 
also conducted risk analysis using residence time distribution models to identify 
the impact of flowrate disturbances on product quality. Consequently, they were 
able to develop risk mitigation strategies to enable continuous production of high 
quality tablet.
4. Conclusion
This chapter discussed quality control of mass production process in the chemi-
cal industry. It reviewed a typical mass production process, identified current 
practice in the industry in order to guarantee quality assurance during mass produc-
tion and finally proposed how this could be implemented in the chemical industry. 
A combination of acceptance sampling and process analytical techniques were 
deemed suitable for quality control during both batch and mass production.
Quality control during bulk pharmaceutical production was studied where 
robots and machines were subjected to decontamination quality control procedure. 
Tableting and encapsulating machines for drug production also needed to be 
properly calibrated and cleaned to ensure constant tablet weight, and also minimise 
contamination of products.
Risk variables Impact from risk negligence
(1) Use of acceptance sampling to evaluate input and 
output materials
(1) (a) Producer’s risk
  (b) Consumer’s risk
(2) Inadequate cleaning of manufacturing equipment (2) Contamination of product with impurities
(3) Chemicals used to decontaminate equipment can 
react with materials
(3) Contamination of product with impurities
(4) Change in powder bulk density during compaction (4) Variation in tablet weight
(5) Impurities in reactant chemicals (5) Impure product
(6) Inaccuracy in the dosing position of the tablet press (6) Variation in tablet weight
(7) Change in filling efficacy due to changes in powder 
flow properties
(7) Variation in tablet weight
Table 2. 
Risk assessment of quality control during mass production.
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Risk assessment of quality control procedures was proposed in order to engender 
quality assurance during mass production.
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